OncoMatch/Clinical Trials/NCT06563388
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
Is NCT06563388 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies non-drug interventions for oligometastasis.
This protocol is comprised of three unblinded, randomized, single-center studies to evaluate the impact of immediate versus three-month delayed comprehensive ablative treatment on survival in newly diagnosed metastatic patients with lung (Trial 1), colorectal (Trial 2), and prostate (Trial 3) cancers
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Colorectal Cancer
Prostate Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Cannot have received: chemotherapy
Exception: allowed if completed >3 weeks prior to study entry (6 weeks for nitrosoureas or mitomycin C) and recovered from adverse events
Participants who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier
Cannot have received: radiotherapy
Exception: allowed if completed >3 weeks prior to study entry (6 weeks for nitrosoureas or mitomycin C) and recovered from adverse events; prior radiotherapy in general is allowed, as long as the composite plan meets dose constraints
Participants who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier. Prior radiotherapy in general is allowed, as long as the composite plan meets dose constraints herein.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Roswell Park Comprehensive Cancer Center · Buffalo, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify